The first FDA-approved generic monensin – available to U.S. beef, dairy, and goat producers as Monovet®90 from global animal health company Huvepharma® – has now also received FDA approval for combination use with other drug feed additive products in the manufacture of Type B and C medicated feeds.
Monovet 90, the generic equivalent to Rumensin® 90, is an ionophore that alters rumen fermentation patterns to increase feed efficiency, particularly among feedlot cattle, and to improve body weight gain of cattle on pasture. The combination approvals allow Monovet 90 to be used with other feed additives commonly fed to feedlot cattle, such as tylosin, ractopamine, and melengestrol. For the list of current medicated feed combinations approved with Monovet 90, visit: https://www.monovet.us
“By bringing the first generic monensin product in the marketplace, Huvepharma offers livestock producers a new cost-effective choice, while providing the same benefits of dosage, chemical identity, potency, quality, safety, and route of administration,” says Glen Wilkinson, president of Huvepharma US.
Wilkinson reports that Huvepharma has a vertically integrated infrastructure in fermentation production which facilitates their core strength in manufacturing medicated feed additives and other critical products for the animal food producing industry. “Monovet 90 is an example of Huvepharma’s commitment to bringing effective and essential choices to the U.S. cattle industry,” Wilkinson says.
Huvepharma has been active in the US animal health market since its inception in 2005 providing products for poultry, swine and cattle markets. The company received FDA approval for Monovet 90 in the U.S. in July 2019, which follows a generic approval for Tylan® (tylosin phosphate) sold as Tylovet®
With the introduction of Monovet 90 for the U.S. market, Huvepharma will continue to focus on building close partnerships with livestock customers, offering high quality products and unparalleled customer service.
Building on its 60-year history, Huvepharma has focused on becoming a fully-integrated company which includes research and development, production, regulatory activity, sales and marketing. The company today ranks 10th among the largest veterinary pharmaceutical companies, and Huvepharma operates three modern and multipurpose fermentation facilities that manufacture active substances, nutritional supplements, enzymes, probiotics and ready medicinal formulations. In addition, the company has just completed an extensive expansion project that increases production capacity 30% thereby insuring consistent supply of the full portfolio of products.
For more information, please contact your Huvepharma sales representative and/or Huvepharma’s Customer Service team at 877-994-4883.
Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. A privately-owned company headquartered in Sofia, Bulgaria, Huvepharma’s U.S. headquarter are located in Peachtree City, GA.